Issue link: https://viewer.e-digitaledition.com/i/802686
IN DECEMBER 2016, A YEAR AND A HALF AFTER THE 21ST CENTURY CURES ACT FIRST PASSED IN THE HOUSE OF REPRESENTATIVES, THE BILL WAS SIGNED INTO LAW, PAVING THE WAY FOR ADVANCED MEDICAL RESEARCH INTO CONDITIONS AND DISEASES THAT AFFECT PEOPLE WITH DOWN SYNDROME. PASSED IN A rare showing of bipartisan support, the 21st Century Cures Act allows for significant increases in federal funding for biomedical research and expedites the U.S. Food and Drug Administration's regulatory review process, among many other provisions. The legislation, which the Global Down Syndrome Foundation fully supported, is the result of two and a half years of work. Originally introduced by Rep. Fred Upton (R-MI) in 2015, the bill lists 230 sponsors from both parties, including Rep. Diana DeGette (D-CO). "Passage of 21st Century Cures is a watershed moment in this country for biomedical research," DeGette said. "With this new law, we bring hope to millions of people who suffer from cancer, Alzheimer's disease, diabetes, and a host of other diseases. It will help overcome obstacles to medical progress — from discovery to development to delivery — through investing in innovation, incorporating the patient perspective, and modernizing clinical trials." IMPROVING QUALITY OF LIFE FOR PEOPLE WITH DOWN SYNDROME People with Down syndrome are at a greater risk than the typical population for a number of conditions, including Alzheimer's disease, autoimmune disorders, and soft-tissue cancers. Much of the bill's total $6.3 billion will go toward research into and treatments for these conditions and many others. Specifically, the law increases the National Institutes of Health's (NIH's) research budget by $4.8 billion over the next 10 years. Those funds will be divided up among a number of NIH initiatives, including: • More than $1.5 billion for the BRAIN Initiative, a project designed to forge new brain-mapping technologies, as well as gain insight into the underlying causes of neurological and psychiatric conditions, including Alzheimer's disease and autism • $1.4 billion for a Precision Medicine Initiative, which will aid in the development of genetic insights and cutting-edge treatments based on collective genetic data; this initiative may spur new understanding of certain genetic abnormalities, such as blood diseases, common in people with Down syndrome. • $1.8 billion earmarked for a cancer research "moonshot" campaign, which will help researchers make breakthroughs in the prevention, diagnosis, and treatment of cancer • $30 million to fund regenerative medicine that will investigate new therapies using adult stem cells The U.S. Food and Drug Administration will receive $500 million over 10 years to expedite the regulatory process for drug and medical device approval, while the remaining $1 billion will fund efforts to combat opioid addiction. Ultimately, the 21st Century Cures Act will help our nation's scientists glean groundbreaking biomedical insights and develop innovative prevention strategies, diagnostic tools, and treatments for conditions that can affect people with Down syndrome. Additionally, it will further sustain the United States' position as a biomedical science leader, empower universities and research organizations across the country to make scientific breakthroughs in some of the most daunting health challenges, and, overall, enhance the health of millions of Americans, including those with Down syndrome. Hope for the Future 21 ST CENTURY CURES ACT: WINTER2017 DOWN SYNDROME WORLD 6

